Shuo Ma

Grants

Grants per year 2007 2011 2012 2013 2014 2019 2024 2027

• 17 Active
• 23 Finished

Grants per year

Search results

• Finished

  Prot #U2-VEN-109: Phase I/II Study of Venetoclax in Combination with Ublituximab and Umbralisib (TGR-1202) in Patients with Relapsed or Refractory CLL/SLL

  Ma, S. (PD/PI)

  TG Therapeutics, Inc.

  4/12/19 → 4/12/24

  Project: Research project

• Prot #BGB-3111-212: An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared with Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma

  Ma, S. (PD/PI)

  PRA Health Sciences, BeiGene Ltd.

  2/8/19 → 2/8/22

  Project: Research project

• Prot #017004: An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

  Ma, S. (PD/PI)

  DrugDev Inc., Juno Therapeutics, Inc.

  1/18/19 → 1/18/25

  Project: Research project

• Prot #INCB50465-204: A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)

  Ma, S. (PD/PI)

  Covance Inc., Incyte Corporation

  1/24/18 → 1/24/21

  Project: Research project

• Prot #MEDI4736-NHL-001: A Phase 1/2, Open Label, Multicenter Study To Assess The Safety And Tolerability Of Durvalumab (Anti-PD-L1 Antibody) As Monotherapy And In Combination Therapy In Subjects With Lymphoma Or Chronic Lymphocytic Leukemia

  Ma, S. (PD/PI)

  ICON plc, Celgene International II Sàrl

  6/30/17 → 6/30/20

  Project: Research project

• Prot #M15-330: A Phase 1b/2 Study of Duvelisib and Venetoclax in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3

  Ma, S. (PD/PI)

  AbbVie Inc.

  3/3/16 → 3/3/19

  Project: Research project

• Prot #M14-032: A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects with Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

  Ma, S. (PD/PI)

  INC Research, LLC, AbbVie Inc.

  12/18/14 → 12/31/22

  Project: Research project

• Prot #PCYC-1127-CA: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Previously Treated Waldenstrom’s Macroglobulinemia

  Ma, S. (PD/PI)

  PPD Development, Pharmacyclics, Inc.

  10/14/14 → 12/31/20

  Project: Research project

• Prot #PCYC-1121-CA: A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Relapsed/Refractory Marginal Zone Lymphoma

  Ma, S. (PD/PI)

  PRA Health Sciences, Pharmacyclics, Inc.

  4/24/14 → 3/31/18

  Project: Research project

• Prot #M13-982: A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion

  Ma, S. (PD/PI)

  AbbVie Inc.

  11/11/13 → 11/30/22

  Project: Research project

• Prot #PCYC-1117-CA: An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion

  Ma, S. (PD/PI)

  Quintiles, Inc., Pharmacyclics, Inc.

  4/22/13 → 6/20/15

  Project: Research project

• Prot #PCYC-1112-CA: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  Ma, S. (PD/PI)

  Pharmacyclics, Inc.

  3/26/13 → 11/30/14

  Project: Research project

• Prot #GAO4753g: An Open-Label, Multicenter, Randomized, Phase III Study To Investigate The Efficacy And Safety of Bendamustine Compared With Bendamustine + RO5072759 (GA101) In Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma

  Ma, S. (PD/PI)

  INC Research, LLC, Genentech, Inc

  1/28/13 → 1/28/19

  Project: Research project

• Prot #GS-US-312-0117: A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS-1101 (CAL-101) as Therapy for Patients with Previously Treated Chronic Lymphocytic Leukemia

  Ma, S. (PD/PI)

  PPD Development, Gilead Sciences, Inc

  9/28/12 → 9/28/18

  Project: Research project

• Prot #GS-US-312-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia

  Ma, S. (PD/PI)

  PPD Development, Gilead Sciences, Inc

  9/28/12 → 9/28/15

  Project: Research project

• Prot #M13-365: A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination with Rituximab in Subjects with Relapsed Chronic Lymphocytic Leukemia

  Ma, S. (PD/PI)

  Abbott Laboratories

  6/29/12 → 2/25/24

  Project: Research project

• Prot#MCC-12215(X05240)//NU VC11H12: Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma

  Ma, S. (PD/PI)

  Virginia Commonwealth University, Millennium Pharmaceuticals, Inc.

  6/6/12 → 6/6/15

  Project: Research project

• Prot#AVL-292-003: Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects with Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulin

  Ma, S. (PD/PI)

  INC Research, LLC, Avila Therapeutics, Inc.

  3/28/12 → 3/28/18

  Project: Research project

• Prot#101-09: APhase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents

  Ma, S. (PD/PI)

  INC Research, LLC, Gilead Calistoga, LLC

  2/20/12 → 2/10/18

  Project: Research project

• Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma

  Ma, S. (PD/PI)

  Virginia Commonwealth University, National Cancer Institute

  8/1/11 → 7/31/13

  Project: Research project

• Agmt 01/07/11: Connect CLL: The Chronic Lymphocytic Leukemia Disease Registry

  Ma, S. (PD/PI)

  Outcome Sciences Inc., Celgene Corporation

  1/7/11 → 3/31/18

  Project: Research project

• Exploring Glucocorticoid-Induced Cytotoxicity in Chronic Lympocytic Leukemia

  Ma, S. (PD/PI)

  Leukemia & Lymphoma Society

  7/1/09 → 6/30/12

  Project: Research project

• Understanding the Role of NALP11 and NALP7 Genes in Myeloma Glucoccorticoid Resistance

  Ma, S. (Other)

  American Society of Clinical Oncology

  7/1/07 → 6/30/08

  Project: Research project